РАЗЛИЧНЫЕ ВИДЫ АНТИКОАГУЛЯНТНОЙ ТЕРАПИИ У БОЛЬНЫХ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА И СВЯЗАННЫЕ С НЕЙ ОСЛОЖНЕНИЯ ЖКТ

In ischemic heart disease (CHD), progressive disorders of the hemostasis system are corrected with shorter and longer antiplatelet therapy. However, recent studies have consistently demonstrated the development of up to 25 % of all possible side effects and complications of anticoagulant and antiplatelet therapy. Purpose of the study: to study the use of anticoagulant therapy in patients with ischemic heart disease and to identify adverse effects on the gastrointestinal tract. Material and research methods. 146 patients with ischemic heart disease (CHD), were examined, among whom there were 12 (8,22 %) patients with acute myocardial infarction (MI), 68 (46,57 %) with progressive intense angina pectoris (PNS), tense angina pectoris (NS, functional class III–IV) – 66 (45,21 %) people and 71 patients with chronic peptic ulcer disease without ischemic heart disease. The average age of the patients was 56,3 ± 2,4 years. Research results: in the present study, the «ulcerative» history was assessed and whether there was a complication (bleeding, penetration or perforation). Conclusion: thus, the emergence and development of erosive and ulcerative lesions in patients with coronary heart disease is largely promoted by the use of antiplatelet or anticoagulant drugs.